Asked about the strategic priorities in the US, he added: “Not only the US, but we have interest in selling innovative medicines globally… for emerging markets we are looking at tuck-ins or smaller acquisitions which we can look at integrating with our existing business to get scale in the emerging markets.” Shanghvi added.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets